AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9163557 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha2,3-sialyltransferase mRNA expression in glioma specimens and brain tumor cell lines
Number of subjects: 0
Study 9163557 — intervention group
Group type: EXPERIMENTAL
Intervention: Maackia amurensis agglutinin staining
Number of subjects: 0
Study 9163557 — intervention group
Group type: COMPARATOR
Intervention: Normal human adult astrocytes
Number of subjects: 0
Study 8214656 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml of bupivacaine (0.25%; 50 mg) intra‐articularly (IA) (Group 1)
Number of subjects: 60
Study 8214656 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous three‐in‐one lumbar plexus block using a catheter to administer 0.25 ml/kg of bupivacaine (0.25%; single‐shot) plus continuous pump infusion of the same drug (0.03 ml.kg‐1 x h‐1 of 0.25% bupivacaine for 24 h) (Group 2)
Number of subjects: 60
Study 8214656 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of morphine with 20 ml of saline IA (Group 3)
Number of subjects: 60
Study 3735103 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg dothiepin hydrochloride
Number of subjects: 27
Study 3735103 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg dothiepin hydrochloride
Number of subjects: 27
Study 3735103 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg dothiepin hydrochloride
Number of subjects: 27
Study 3735103 — intervention group
Group type: EXPERIMENTAL
Intervention: S-oxide derivative of dothiepin (metabolite 2)
Number of subjects: 27
Study 3735103 — intervention group
Group type: EXPERIMENTAL
Intervention: Demethyl S-oxide derivative (metabolite 4)
Number of subjects: 27
Study 3735103 — intervention group
Group type: EXPERIMENTAL
Intervention: Demethyl derivative (metabolite 3)
Number of subjects: 27
Study 3735103 — intervention group
Group type: EXPERIMENTAL
Intervention: Three metabolites (S-oxide 2, demethyl 3, demethyl S-oxide 4)
Number of subjects: 27
Study 11956896 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 17
Study 29462503 — intervention group
Group type: EXPERIMENTAL
Intervention: SL-SAT
Number of subjects: 240
Study 29462503 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study 29462503 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 240
Study 27145327 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltitrexed + OXA-based TACE
Number of subjects: 227
Study 27145327 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil + OXA-based TACE
Number of subjects: 227
Study 27145327 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin + OXA-based TACE
Number of subjects: 227
Study 24321538 — intervention group
Group type: EXPERIMENTAL
Intervention: Trophic feeds
Number of subjects: 34
Study 24321538 — intervention group
Group type: COMPARATOR
Intervention: Nil per os
Number of subjects: 34
Study 22253054 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPAP titration
Number of subjects: 16
Study 22253054 — intervention group
Group type: EXPERIMENTAL
Intervention: DISE CPAP titration
Number of subjects: 16
Study 19686304 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention promoting sun protection and hat use; specific dosage and duration not applicable as this is baseline data before intervention.
Number of subjects: 0
Study 19686304 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline data); no intervention activities initiated yet.
Number of subjects: 0
Study 18825584 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention affecting other-estimates in Study 1 (n=58)
Number of subjects: 350
Study 18825584 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention affecting other-estimates in Study 2 (n=101)
Number of subjects: 350
Study 18825584 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified intervention in Study 3 (n=79)
Number of subjects: 350
Study 18825584 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified intervention in Study 4 (n=112)
Number of subjects: 350
Study 15780546 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based brief motivational intervention (Drinker's Check-up - DCU)
Number of subjects: 61
Study 15780546 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 61
Study 12466733 — intervention group
Group type: EXPERIMENTAL
Intervention: Climodien (2 mg estradiol and 2 mg dienogest)
Number of subjects: 19
Study 12466733 — intervention group
Group type: EXPERIMENTAL
Intervention: Kliogest (2 mg estradiol and 1 mg norethisterone acetate)
Number of subjects: 19
Study 10513444 — intervention group
Group type: EXPERIMENTAL
Intervention: Padded plinth
Number of subjects: 24
Study 10513444 — intervention group
Group type: COMPARATOR
Intervention: Rigid plinth
Number of subjects: 24
Study 7729606 — intervention group
Group type: EXPERIMENTAL
Intervention: IDDM patients with diabetic nephropathy
Number of subjects: 36
Study 7729606 — intervention group
Group type: COMPARATOR
Intervention: Normoalbuminuric IDDM patients
Number of subjects: 36
Study 7729606 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 36
Study 2183633 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral S-adenosylmethionine
Number of subjects: 15
Study 2183633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6445607 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 μg ipratropium bromide
Number of subjects: 20
Study 6445607 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 μg ipratropium bromide
Number of subjects: 20
Study 6445607 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 μg ipratropium bromide
Number of subjects: 20
Study 6445607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29295034 — intervention group
Group type: EXPERIMENTAL
Intervention: Bystander intentions and actions, barriers to bystander action, perceptions of school readiness
Number of subjects: 1150
Study 29295034 — intervention group
Group type: COMPARATOR
Intervention: Exploratory sample (ES)
Number of subjects: 1150
Study 29295034 — intervention group
Group type: COMPARATOR
Intervention: Confirmatory sample (CS)
Number of subjects: 1150
Study 31358107 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hemofiltration combined with octreotide
Number of subjects: 86
Study 31358107 — intervention group
Group type: COMPARATOR
Intervention: Continuous hemofiltration alone
Number of subjects: 86
Study 28233477 — intervention group
Group type: EXPERIMENTAL
Intervention: EasyProsthes composite mesh (EPM)
Number of subjects: 80
Study 28233477 — intervention group
Group type: COMPARATOR
Intervention: Parietex Composite (PCO)
Number of subjects: 80
Study 26823204 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm/benefit presented as ranges (arm 4)
Number of subjects: 147
Study 26823204 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm as point/benefit as range (arm 2)
Number of subjects: 147
Study 26823204 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm as range/benefit as point (arm 3)
Number of subjects: 147
Study 26823204 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm/benefit presented as point-estimates (arm 1)
Number of subjects: 147
Study 25247950 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear blended images at a 25% reduced dose
Number of subjects: 45
Study 25247950 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear blended images at a 50% reduced dose
Number of subjects: 45
Study 25247950 — intervention group
Group type: COMPARATOR
Intervention: Simulated 120-kVp linear blended images at a full dose
Number of subjects: 45
Study 21993852 — intervention group
Group type: EXPERIMENTAL
Intervention: Billroth I (B-I)
Number of subjects: 332
Study 21993852 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y (R-Y)
Number of subjects: 332
Study 19663758 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum and counseling
Number of subjects: 755
Study 19663758 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline confidence to quit
Number of subjects: 755
Study 19663758 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 755
Study 19663758 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 755
Study 19663758 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced confidence to quit between baseline and week 26
Number of subjects: 755
Study 18508120 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS involvement at diagnosis
Number of subjects: 104
Study 18508120 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation (SCT)
Number of subjects: 104
Study 18508120 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 104
Study 18508120 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 104
Study 18508120 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-free survival (DFS)
Number of subjects: 104
Study 18508120 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS recurrence after first relapse
Number of subjects: 104
Study 18508120 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) after first relapse
Number of subjects: 104
Study 18508120 — intervention group
Group type: COMPARATOR
Intervention: CNS involvement at diagnosis vs. no CNS disease
Number of subjects: 104
Study 18508120 — intervention group
Group type: COMPARATOR
Intervention: CNS recurrence vs. relapsing patients without CNS disease
Number of subjects: 104
Study 15974484 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinwei Decoction
Number of subjects: 73
Study 15974484 — intervention group
Group type: COMPARATOR
Intervention: Domperidone
Number of subjects: 73
Study 15974484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 12640339 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (n=44)
Number of subjects: 84
Study 12640339 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrates (n=22)
Number of subjects: 84
Study 12640339 — intervention group
Group type: COMPARATOR
Intervention: Hypolipidemiant diet (Control group, n=18)
Number of subjects: 84
Study 10886086 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg of MUSE
Number of subjects: 166
Study 10886086 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg of MUSE
Number of subjects: 166
Study 10886086 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 microg of MUSE
Number of subjects: 166
Study 10886086 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 microg plus a pubic band
Number of subjects: 166
Study 10886086 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower doses (125, 250, 500 microg)
Number of subjects: 166
Study 8817225 — intervention group
Group type: EXPERIMENTAL
Intervention: Duct to mucosa anastomosis
Number of subjects: 93
Study 8817225 — intervention group
Group type: COMPARATOR
Intervention: Invaginating pancreaticojejunostomy
Number of subjects: 93
Study 1433771 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-lumen catheter
Number of subjects: 177
Study 1433771 — intervention group
Group type: COMPARATOR
Intervention: Single-lumen catheter
Number of subjects: 177
Study 12267106 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravigard (Cu 7)
Number of subjects: 199
Study 12267106 — intervention group
Group type: EXPERIMENTAL
Intervention: Lippes Loop D
Number of subjects: 199
Study 12267106 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu 220C
Number of subjects: 199
Study 31136927 — intervention group
Group type: EXPERIMENTAL
Intervention: MyTEP (Therapeutic Education Program plus smartphone app)
Number of subjects: 50
Study 31136927 — intervention group
Group type: COMPARATOR
Intervention: mHP (smartphone app)
Number of subjects: 50
Study 31136927 — intervention group
Group type: COMPARATOR
Intervention: MyTEP vs mHP
Number of subjects: 50
Study 28664624 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (≥75% session attendance)
Number of subjects: 234
Study 28664624 — intervention group
Group type: COMPARATOR
Intervention: Intensive lifestyle intervention (<75% session attendance)
Number of subjects: 234
Study 28664624 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall session attendance
Number of subjects: 234
Study 28664624 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of diet and physical activity
Number of subjects: 234
Study 26950553 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg quetiapine IR
Number of subjects: 40
Study 26950553 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg escitalopram
Number of subjects: 40
Study 26950553 — intervention group
Group type: COMPARATOR
Intervention: 400 mg moxifloxacin (positive control)
Number of subjects: 40
Study 26950553 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 22953510 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing for Recovery group intervention (experimental group, n = 29)
Number of subjects: 61
Study 22953510 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 32)
Number of subjects: 61
Study 20726909 — intervention group
Group type: EXPERIMENTAL
Intervention: GP Removal
Number of subjects: 75
Study 20726909 — intervention group
Group type: COMPARATOR
Intervention: GP No Removal
Number of subjects: 75
Study 20726909 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon Removal
Number of subjects: 75
Study 20726909 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA Removal
Number of subjects: 75
Study 20726909 — intervention group
Group type: COMPARATOR
Intervention: Control (Gutta-percha and TubliSeal sealer)
Number of subjects: 75
Study 18608021 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior ultrasonography-guided contrast injections
Number of subjects: 43
Study 18608021 — intervention group
Group type: COMPARATOR
Intervention: Posterior ultrasonography-guided contrast injections
Number of subjects: 43
Study 16080637 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous lateral internal sphincterotomy using radiofrequency bistoury (Group A)
Number of subjects: 35
Study 16080637 — intervention group
Group type: COMPARATOR
Intervention: Conventional lateral internal sphincterotomy (Group B)
Number of subjects: 35
Study 12501499 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 18
Study 12501499 — intervention group
Group type: COMPARATOR
Intervention: Elemental diet, semi-elemental diet, polymeric diet
Number of subjects: 18
Study 12501499 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with n-3-fatty acids
Number of subjects: 18
Study 12501499 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet
Number of subjects: 18
Study 12501499 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with dietary fiber
Number of subjects: 18
Study 12501499 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination diet
Number of subjects: 18
Study 12501499 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with olestra
Number of subjects: 18
Study 9613225 — intervention group
Group type: EXPERIMENTAL
Intervention: HCI tasks (text editing, executing a tutor program or programming, playing Tetris)
Number of subjects: 49
Study 9613225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tasks (intelligence test/programming)
Number of subjects: 49
Study 9613225 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-based tasks (sensation seeking/Tetris)
Number of subjects: 49
Study 9613225 — intervention group
Group type: EXPERIMENTAL
Intervention: Executing the tutor program or programming
Number of subjects: 49
Study 9613225 — intervention group
Group type: EXPERIMENTAL
Intervention: All observed after-effects
Number of subjects: 49
Study 8026448 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg at 01:30 and 07:30
Number of subjects: 24
Study 8026448 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of prophylactic nap and caffeine
Number of subjects: 24
Study 8026448 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 24
Study 8026448 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 24
Study 2685288 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal antiinflammatory drugs (NSAIDs)
Number of subjects: 0
Study 2685288 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer NSAIDs
Number of subjects: 0
Study 2685288 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild analgesics
Number of subjects: 0
Study 2685288 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and ibuprofen
Number of subjects: 0
Study 2685288 — intervention group
Group type: COMPARATOR
Intervention: Placebo or acetaminophen
Number of subjects: 0
Study 1096219 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mug/kg (‐‐)delta‐9‐trans‐tetrahydrocannabinol p.o.
Number of subjects: 36
Study 1096219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 30332535 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-based intervention introducing eggs into the complementary feeding diet
Number of subjects: 0
Study 30332535 — intervention group
Group type: EXPERIMENTAL
Intervention: Social marketing strategy
Number of subjects: 0
Study 26827260 — intervention group
Group type: EXPERIMENTAL
Intervention: Papain meat tenderizer
Number of subjects: 96
Study 26827260 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 96
Study 26827260 — intervention group
Group type: COMPARATOR
Intervention: Acetic acid
Number of subjects: 96
Study 26827260 — intervention group
Group type: COMPARATOR
Intervention: Isopropyl alcohol
Number of subjects: 96
Study 26827260 — intervention group
Group type: COMPARATOR
Intervention: Heated water
Number of subjects: 96
Study 26827260 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 96
Study 26827260 — intervention group
Group type: COMPARATOR
Intervention: Papain
Number of subjects: 96
Study 24299975 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotaverine hydrochloride (40mg) given at the start of the active phase of labor, repeated every 2 hours (maximum 3 doses)
Number of subjects: 320
Study 24299975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 22578232 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 20 mg
Number of subjects: 24
Study 22578232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 20929464 — intervention group
Group type: EXPERIMENTAL
Intervention: Sisters in Motion intervention (multicomponent curriculum including scripture readings, prayer, goal-setting, community resource guide, and walking competitions)
Number of subjects: 62
Study 20929464 — intervention group
Group type: COMPARATOR
Intervention: Control group (participated in physical activity sessions)
Number of subjects: 62
Study 18807576 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-hydrochlorothiazide film-coated tablet formulation
Number of subjects: 73
Study 18807576 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide film-coated tablet formulation
Number of subjects: 73
Study 18807576 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan carboxy acid
Number of subjects: 73
Study 16204712 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET scan
Number of subjects: 30
Study 16204712 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE genotype assessment
Number of subjects: 30
Study 16204712 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of (18)F‐FDG PET and APOE genotype
Number of subjects: 30
Study 16204712 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of probable DAT
Number of subjects: 30
Study 12074410 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised method for assessing maximum urinary flow
Number of subjects: 223
Study 12074410 — intervention group
Group type: COMPARATOR
Intervention: Expert assessments (3 experts)
Number of subjects: 223
Study 10207659 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20‐80 mg/day)
Number of subjects: 180
Study 10207659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 8597527 — intervention group
Group type: EXPERIMENTAL
Intervention: Flesinoxan (7 and 14 micrograms/kg, IV)
Number of subjects: 23
Study 8597527 — intervention group
Group type: EXPERIMENTAL
Intervention: Flesinoxan (1 mg, IV)
Number of subjects: 23
Study 2623036 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein breakfast
Number of subjects: 0
Study 2623036 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate breakfast
Number of subjects: 0
Study 2623036 — intervention group
Group type: EXPERIMENTAL
Intervention: 0% protein breakfast
Number of subjects: 0
Study 2623036 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate breakfasts containing 4, 8, or 12% protein
Number of subjects: 0
Study 2623036 — intervention group
Group type: EXPERIMENTAL
Intervention: Danish pastry
Number of subjects: 0
Study 320810 — intervention group
Group type: EXPERIMENTAL
Intervention: Carticaine 2% with adrenaline 1:200,000
Number of subjects: 0
Study 320810 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2% with adrenaline 1:200,000
Number of subjects: 0
Study 6123363 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers (late intervention)
Number of subjects: 17
Study 6123363 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers (early intervention)
Number of subjects: 17
Study 31274194 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Learning Method (DLM)
Number of subjects: 115
Study 31274194 — intervention group
Group type: COMPARATOR
Intervention: Knowledge-Based Method (KBM)
Number of subjects: 115
Study 31274194 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Method (KBM + DLM)
Number of subjects: 115
Study 27444046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact oxycodone 40 mg, intact OxyContin® 40 and 80 mg, crushed OxyContin® 40 mg, and placebo (Cohort 1)
Number of subjects: 35
Study 27444046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact oxycodone 20, 40, and 80 mg and placebo (Cohort 2)
Number of subjects: 35
Study 27444046 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar scales
Number of subjects: 35
Study 27444046 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar scales
Number of subjects: 35
Study 26916685 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 1-3 times daily
Number of subjects: 412